Table 2.
Sample numbers post-QC
| TNFi | Phenotype, n (imputation group 1 / 2 / 3) | ||||
|---|---|---|---|---|---|
| ΔDAS28 | ΔESR | ΔSJC28 | ΔTJC28 | ΔPGA | |
| Adalimumab | 500 (171/284/45) | 487 (162/282/43) |
551 (169/339/43) | 551 (169/339/43) | 549 (167/339/43) |
| Etanercept | 564 (309/243/12) |
549 (297/240/12) |
619 (304/303/12) | 619 (304/303/12) | 615 (301/302/12) |
| Infliximab | 441 (331/56/54) |
414 (310/53/51) |
434 (319/63/52) | 434 (319/63/52) | 426 (313/62/51) |
| Other | 64 (0/64/0) | 64 (0/64/0) | 119 (0/119/0) | 119 (0/119/0) | 119 (0/119/0) |
| Total |
1569
(811/647/111) |
1514
(769/639/106) |
1723
(792/824/107) |
1723
(792/824/107) |
1709
(781/822/106) |